MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Partnership Leverages Syntekabio's DeepMatcher® Platform to Expand the Therapeutic Potential of
MetaVia's Oral GPR119 Agonist

CAMBRIDGE, Mass., Aug. 4, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a research collaboration with Syntekabio, Inc., a leading artificial intelligence (AI)-driven drug discovery company, to identify additional disease targets and optimize the therapeutic profile of DA-1241, MetaVia's novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist.

Read more at prnewswire.com